Jump to content

Speakers


Professor Michel Burnier, University of Lausanne, Switzerland

M. Burnier is Emeritus Professor at the University of Lausanne where he is has been the Head of Nephrology and Hypertension for 14 years Member of the council of the ESH for many years, his main research interests are the role of salt in the pathophysiology of hypertension, the pharmacological development of new antihypertensive drugs and drug adherence.
Professor Chris Byrne, University of Southampton, UK


Professor Byrne trained in the UK and the US, at Cardiff, Cambridge and Stanford Universities. Prof Byrne was appointed in 1999 to the Chair of Endocrinology & Metabolism at the University of Southampton and has published over 300 peer reviewed papers related to metabolic syndrome and non-alcoholic fatty liver disease.

President

Professor Francesco Cappuccio
Professor Lucy Chappell, King’s College, UK

Professor Lucy Chappell is NIHR Research Professor in Obstetrics at King’s College London and Honorary Consultant Obstetrician at Guy’s and St Thomas’ NHS Foundation Trust, running a research programme investigating prediction and prevention of adverse pregnancy outcomes, particularly in women with pre-existing co-morbidities such as chronic hypertension and chronic kidney disease.
Professor Lyne Cloutier
Mrs Elizabeth Denver, Royal Free and University College London Medical School, UK

Elizabeth is the Hypertension Nurse Member of the NICE Guidelines Committee reviewing Hypertension in adults. She qualified in 1977 and later became a diabetes and cardiovascular research Nurse. In 2000 she started a Nurse-Led Hypertension Clinic. Elizabeth is a member of the BIHS Blood Pressure Measurement and AHP Working Parties.
Professor Caroline Fall, University of Southampton, UK

Professor Caroline Fall is a paediatrician and epidemiologist at the University of Southampton. Her research focuses on the early life origins of cardiovascular disease and type 2 diabetes, through studies linking maternal nutrition, fetal development and CVD risk markers in children. Most of her current research is in low- and middle-income countries.
Dr Mark Glover, Nottingham, UK

Mark trained in pre-clinical pharmacology and clinical medicine at Gonville and Caius College, Cambridge. His clinical and research interests are in hypertension and the identification of novel anti-hypertensive drug targets by understanding the molecular pathophysiology of sodium reabsorption in the distal nephron. He leads the hypertension clinic in Nottingham.
Mark’s current research is focussed on the molecular pathophysiology of sodium reabsorption via the thiazide-sensitive pathway, based on genetic analysis of individuals with the Mendelian Gordon syndrome and Thiazide-Induced Hyponatraemia in those with essential hypertension.
Mark’s other interests are in medical education and general (internal) medicine. He is a member of the Prescribing Safety Assessment Board for UK medical students, an associate member of the Higher Education Academy, a member of NICE Technology Appraisal Committee B, the NICE hypertension in adults guideline committee and the MHRA Pharmaco-vigilance committee.
Professor Philip Kalra

Professor Philip Kalra has a major research focus on renovascular disease, cardiovascular disease in CKD and the progression and epidemiology of non-dialysis CKD. He is Academic Vice President of the UK Renal Association and was NIHR CRN Renal Disorders Chair until late 2018.
Professor Janet Lord, Birmingham University, UK

Professor Janet Lord is director of the Institute of Inflammation and Ageing at Birmingham University, she is also director of the MRC-ARUK Centre for Musculoskeletal Ageing Research. Her main research interest is how inflammation drives the ageing process and lead to frailty and multimorbidity and how to minimise ageing processes.
Miss Judith Magowan,

Miss Judith Magowan works as a prescribing nurse in Primary Care where she is the Long Term Condition lead. She set up their nurse-led hypertension clinic in 2010. Since completing a post graduate certificate in education in 2009, she has worked as an associate lecturer developing and delivering modules, study days and updates on asthma, COPD and Spirometry, cardiovascular disease and hypertension. Miss Magowan has been delivering a BIHS approved study day on nurse-led hypertension across Devon and Cornwall through the Community Education Network Provider.
Professor Richard Mcmanus, Oxford, UK

Richard McManus is Professor of Primary Care Research and a part time GP in Oxford. His research interests lie mainly in the prevention of cardiovascular disease with particular emphasis on blood pressure measurement and management of hypertension in primary care where his work has influenced National and International Clinical Guidelines.
Dr Sunil Nadar, Sultan Qaboos University Hospital, Oman

Dr Nadar is a consultant interventional cardiologist at the Sultan Qaboos University Hospital. He is also the editor with Journal of Human Hypertension.
Professor Gianfranco Parati, St Luca Hospital, Italy

Head, Dept Cardiology St Luca Hospital, Milan; Scientific Director, Istituto Auxologico Italiano, Milan; Professor of Cardiovascular Medicine, University of Milano-Bicocca, Milan, Italy. Past President, Italian Society of Hypertension. Past Chairman, ESH working groups on Blood pressure monitoring and blood pressure variability. Fellow of the European Society of Cardiology. Liaison Officer, Nucleus Board of ESC Council on Hypertension. Secretary general and Executive Board Member, WHL

Dr James Sheppard
2 year term of office
2017 - 2019

Dr James Sheppard, University of Oxford, UK

James is a Population Health Scientist interested in better understanding the benefits and harms of treatments, with a particular focus on cardiovascular disease prevention. His research aims to develop tools which improve the targeting of preventative therapies such as antihypertensives and statins at patients with the most to gain.

He leads the Stratified Treatments Research Group at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. His group is interested in developing prognostic models for treatment harms using data from large electronic health record databases. In addition he is interested in developing new strategies to deal with polypharmacy and currently leads a randomised controlled trial of antihypertensive deprescribing in patients over the age of 80 years.


Dr Laurie Tomlinson, London School of Hygiene and Tropical Medicine, UK

Laurie Tomlinson is a Wellcome and Intermediate Fellow and Associate Professor at the London School of Hygiene and Tropical Medicine as well as an honorary Consultant Nephrologist at Brighton and Sussex University Hospital. Her main research interest is the use of electronic health records to investigate kidney-related adverse events for prescribed medication.
Dr Maria-Christina Zennaro, French National Institute of Health and Medical Research, France

Maria-Christina Zennaro is Research Director at the French National Institute of Health and Medical Research (Inserm), head of the team “Genetic mechanisms of aldosterone related disorders” at the Paris Cardiovascular Research Center and associated investigator at the Genetics Department of the European Hospital Georges Pompidou (HEGP) in Paris, France.